The Medical Letter on Drugs and Therapeutics
Carfilzomib (Kyprolis) for Multiple Myeloma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved carfilzomib (Kyprolis – Onyx), a proteasome inhibitor, for intravenous treatment of refractory multiple myeloma. Bortezomib (Velcade) was the first proteasome inhibitor to be approved for this indication.1

BORTEZOMIB — Use of drug regimens that include bortezomib and an immunomodulator such as lenalidomide (Revlimid)2 to treat multiple myeloma has led to improved response rates and survival. However, many patients do not respond to treatment or discontinue these drugs due to their toxicity; among those who do respond, the majority eventually relapse.

MECHANISM OF ACTION — Carfilzomib is a selective irreversible proteasome inhibitor.3 It has been shown to induce apoptosis and cell cycle arrest in myeloma cell lines, including some ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Carfilzomib (Kyprolis) for Multiple Myeloma
Article code: 1406c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian